.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Cerilliant
Argus Health
AstraZeneca
Julphar
Colorcon
Baxter
Cantor Fitzgerald
Queensland Health
Healthtrust

Generated: November 22, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,973,058

« Back to Dashboard

Which drugs does patent 7,973,058 protect, and when does it expire?


Patent 7,973,058 protects ZECUITY and is included in one NDA.

This patent has twenty patent family members in twelve countries.

Summary for Patent: 7,973,058

Title:Transdermal methods and systems for the delivery of anti-migraine compounds
Abstract: Iontophoretic patches for the delivery of anti-migraine compounds and methods of using the patches are described.
Inventor(s): Anderson; Carter R. (Inver Grove Heights, MN), Morris; Russell L. (Lindstrom, MN), Sebree; Terri B. (Gladwyne, PA)
Assignee: NuPathe, Inc. (Conshohocken, PA)
Application Number:12/181,142
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Teva Branded Pharm
ZECUITY
sumatriptan succinate
SYSTEM;IONTOPHORESIS202278-001Jan 17, 2013DISCNYesNo► Subscribe► Subscribe METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,973,058

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,470,853Transdermal methods and systems for the delivery of anti-migraine compounds► Subscribe
9,272,137Transdermal methods and systems for the delivery of anti-migraine compounds► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,973,058

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2007238685► Subscribe
BrazilPI0709965► Subscribe
Canada2650412► Subscribe
Canada2935569► Subscribe
China101472644► Subscribe
China104138634► Subscribe
Eurasian Patent Organization023147► Subscribe
Eurasian Patent Organization200802146► Subscribe
European Patent Office2012871► Subscribe
Hong Kong1203867► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Merck
Daiichi Sankyo
Argus Health
Fuji
Baxter
Chubb
Julphar
Cantor Fitzgerald
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot